Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers

Phospholamban (PLN) p.Arg14del mutation carriers are at risk of developing malignant ventricular arrhythmias (VAs) and/or heart failure. Currently, left ventricular ejection fraction (LVEF) plays an important role in risk assessment for VA in these individuals. We aimed to study the incremental prog...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal cardiovascular imaging 2022-10, Vol.23 (11), p.1492-1501
Main Authors: Taha, Karim, Verstraelen, Tom E, de Brouwer, Remco, de Bruin-Bon, Rianne H A C M, Cramer, Maarten J, Te Rijdt, Wouter P, Bouma, Berto J, de Boer, Rudolf A, Doevendans, Pieter A, Asselbergs, Folkert W, Wilde, Arthur A M, van den Berg, Maarten P, Teske, Arco J
Format: Article
Language:English
Subjects:
Original Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phospholamban (PLN) p.Arg14del mutation carriers are at risk of developing malignant ventricular arrhythmias (VAs) and/or heart failure. Currently, left ventricular ejection fraction (LVEF) plays an important role in risk assessment for VA in these individuals. We aimed to study the incremental prognostic value of left ventricular mechanical dispersion (LVMD) by echocardiographic deformation imaging for prediction of sustained VA in PLN p.Arg14del mutation carriers. We included 243 PLN p.Arg14del mutation carriers, which were classified into three groups according to the '45/45' rule: (i) normal left ventricular (LV) function, defined as preserved LVEF ≥45% with normal LVMD ≤45 ms (n = 139), (ii) mechanical LV dysfunction, defined as preserved LVEF ≥45% with abnormal LVMD >45 ms (n = 63), and (iii) overt LV dysfunction, defined as reduced LVEF
ISSN:2047-2404
2047-2412
DOI:10.1093/ehjci/jeab178